GE Healthcare and Thomson Reuters Provide Analytics on Powerful, Precise Clinical Research Dataset
(NewDesignWorld Press Center) - Pharmaceutical firms and other healthcare organizations will now be able to conduct evidence-based research on data that enables them to better quantify the effectiveness of medical treatments on discrete patient populations , thanks to a new data and analytics solution developed and delivered by GE Healthcare and Thomson Reuters.
When needed to answer appropriate population-based health economics and outcomes research questions, healthcare analytics teams at General Electric (NYSE: GE) and Thomson Reuters (NYSE: TRI) now have the ability to combine commonly used outcomes research data from the Thomson Reuters MarketScan® Research Databases with de-identified electronic medical records data, while maintaining patient privacy and full compliance with HIPAA standards.. As a result, researchers and physicians can now gain new evidence-based insights into treatment protocols. These insights can help drive improved health outcomes.
The addition of de-identified clinical data provided by healthcare providers using EMR means a research study can evaluate medical treatments - commonly called "outcomes research" or "comparative effectiveness research." The addition of the de-identified clinical data from the EMR means a research study can link de-identified claims data from a population of patients diagnosed with a particular condition such as hypertension, with de-identified clinical data on everything from a patient's body mass index, blood pressure, symptoms and more. This research would provide more specific evidence to enable clinicians and patients to make better informed decisions.